Effect of anti-herpes specific transfer factor.
Using a blood cell separator, lymphocytes were collected from otherwise healthy convalescents suffering from herpetic infections. A specific anti-herpes dialysate (AH-DLE) was prepared from the lymphocytes, using standard procedures. Patients with recurrent herpetic infections were treated with a single dose of the dialysate, at the initial signs of herpetic infection (group A), with two doses (group B) or with three doses (group C). A total number of 37 patients (29 women, 8 men, age range 15-73 years) were treated. No improvement was observed in 7 patients (18.9%), whilst 7 patients did not manifest any exacerbation of their herpetic infection in the course of the one-year follow-up. The remaining 62.2% of the patients showed a marked improvement: decrease of the frequency and/or duration or relapses. Before AH-DLE administration, the mean number of herpes relapses in this group of patients was 12 p.a.. After therapy, the number of relapses decreased to 3.5 p.a.. No statistically significant difference was observed between groups A and B. The least favourable results were registered in group C. However, this group included 6 female patients extremely resistant to the previously therapeutic attempts, including inosiplex, non-specific DLE or acyclovir. Thus, even in this group, the therapy was successful in 50% of the patients.
Byston
J
J
Dept. of Allergology and Clinical Immunology, Faculty Hospital, Olomouc, Czech Republic.
Cech
K
K
Pekarek
J
J
Jilkova
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D003956:Dialysis; D004305:Dose-Response Relationship, Drug; D005260:Female; D006561:Herpes Simplex / Q000276:immunology / Q000628:therapy; D006562:Herpes Zoster / Q000276:immunology / Q000628:therapy; D006566:Herpesviridae Infections / Q000276:immunology / Q000628:therapy*; D006801:Humans; D008214:Lymphocytes / Q000737:chemistry / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012680:Sensitivity and Specificity; D018139:Simplexvirus / Q000276:immunology*; D014165:Transfer Factor / Q000627:therapeutic use*
D000998:Antiviral Agents; D014165:Transfer Factor